Srolimus    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
89Lymphangioleiomyomatosis1

89. Lymphangioleiomyomatosis    [ 38 clinical trials,   42 drugs,   (DrugBank: 19 drugs),   26 drug target genes,   134 drug target pathways]
Searched query = "Lymphangioleiomyomatosis", "LAM"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 38 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-JMA-IIA00096
05/09/201217/08/2012multicenter lymphangioleiomyomatosis sirolimus trial for safetymulticenter lymphangioleiomyomatosis sirolimus trial for safety lymphangioleiomyomatosisIntervention type:DRUG. Intervention1:Srolimus, Dose form:TABLET, Route of administration:ORAL, intended dose regimen:LAM patients will be medicated with 2mg of sirolimus every day for 2 years and modified dosage between 1mg and 3mg QD depend on the plasma concentration monitoring..Koh Nakata, MD, PhDYoshikazu InoueKuniaki SeyamaRyushi TazawaToshinori TakadaCompleted>=18 YEARSNo LimitFemale65Phase 2Japan